Kerri FitzgeraldMantle Cell Lymphoma | October 5, 2022
Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.
Read More
Kerri FitzgeraldMyelodysplastic Syndromes | October 4, 2022
A study showed "unexpected" results related to race and MDS survival...
Kerri FitzgeraldAcute Myeloid Leukemia | October 3, 2022
The efficacy of enasidenib in patients with AML depends on the mutation type.
Kerri FitzgeraldAcute Lymphoblastic Leukemia | September 30, 2022
Blood Cancers Today Associate Editor Elias Jabbour, MD, gave his thoughts on the first day of the 2022 SOHO Annual Meeting.
Cecilia BrownChronic Lymphocytic Leukemia | September 30, 2022
As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies.
Kerri FitzgeraldChronic Myeloid Leukemia | September 29, 2022
SOHO President Moshe Talpaz, MD, shares how it feels to be back onsite for the Annual Meeting.
Kerri FitzgeraldAcute Lymphoblastic Leukemia | September 28, 2022
The 2022 SOHO Annual Meeting kicked off with remarks from 2022-2023 President Moshe Talpaz, MD.
Leah SherwoodPrint | September 13, 2022
In his President's Letter, Moshe Talpaz, MD, discusses all of the treatment progress made for hematologic malignancies.
Kerri FitzgeraldChronic Lymphocytic Leukemia | September 13, 2022
President-Elect Jennifer R. Brown, MD, PhD, will take office during the 10th Annual SOHO Conference.
Leah SherwoodPrint | August 6, 2022
Dr. Garcia-Manero discusses research from the MDS/AML Moon and what he’s looking forward to as President-Elect of SOHO.
Editorial Board